| Title | In vitro susceptibility of oral candida species to antifungal agents in renal transplant recipients | |
| Author | M. Belazi1, A. Velegraki2, Th. Koussidou-Eremondi3, D. Andreadis1, F. Solonaki4, S. Hini2 and D. Antoniades1
1Dept.of Oral Medicine/Maxillofacial Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece. 2Mycology Reference Laboratory (KEEL), Dept, of Microbiology, School of Medicine, University of Athens, Greece. 3State Hospital of Skin and venereal Diseases, Mycology Laboratory, Thessaloniki, Greece. 4Dept.of Solid Organ Transplantation, Hippokration Hospital of Thessaloniki, Greece |
|
| Citation | Belazi, M., Velegraki, A., Koussidou-Eremondi, T., Andreadis, D., Solonaki, F., et al.: In vitro susceptibility of oral candida species to antifungal agents in renal transplant recipients, Epitheorese Klin. Farmakol. Farmakokinet. 18(1): 94-97 (2004) | |
| Publication Date | Accepted for publication: 2004 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) pharmakonpress[at]pharmakonpress[.]gr | |
| Keywords | Oral Candida Species, Antifungal Agents, renal transplant patients | |
| Other Terms | review article | |
| Summary | Fungal infections are considered as a factor implicated in morbidity and mortality of immunocompromising, renal transplant recipients. Although, systemic antifungal prophylaxis is given, resistant strains of Candida and non-Candida species have been isolated. The aim of the present study was to determine the fluconazole, itraconazole, voriconazole, and amphotericin B susceptibility profiles of Candida species isolated from the oral cavity of renal transplant patients. Methods: 124 renal transplant recipients (RTRs) (56 females and 68 males, mean age 46+6 years with a range of 24 to 61 years) and 78 healthy control (HC) subjects, age-and sex-matched were examined. Isolation and presumptive identification followed by a definitive identification of Candida species using an API 32 ID system. All species were also screened by indirect immunofluorescence (IFA) and furthermore PCR test for differentiation between C. albicans and C. dubliniensis isolates was also performed. Susceptibility testing of oral Candida species to antifungal agents (Itraconazole, fluconazole, voriconazole and amphotericin B) included of both Broth microdilution method (BMD) and Quality control (QC). Results: 38 (31%) of the patients had positive cultures with confluent yeast growth. Cultures of clinical material from six patients revealed multiple Candida species in the lesions. C. krusei and C. glabrata fluconazole MIC90 were found increased (range 16->64 pg/ml), whereas no elevated amphotericin B, itraconazole and voriconazole MICs were recorded for the other Candida and Saccharomyces species. Conclusions: MIC testing is indicated for immunocompromised patients at high risk for colonization and infection of Candida species with primary resistance to fluezole, such as C. krusei or C. glabrata, Furthermore, screening mucosal isolates for phenotypic traits such as susceptibility to antifungals, allows the identification of resistant Candida species subpopulations selected during prophylactic or empirical therapy in cases of renal transplant recipients. | |
| References | 1. Coleman D.C., Rinaldi M.G., Haynes K.A., Rex.J.H., Summerbell R.C., Anaissie A.I.: Importance of Candida species other than Candida albicans as opportunistic pathogens. Med. Mycol. 36(Suppl.1): 156-165 (1998)
2. Gupta K.L., Ghosh A.K., Kochhar R„ lha V., Chakrabarti A., Sakhuja V.: Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. Am. J. Gastroenterol. 89. 1062- 1065 (1994) 3. Sullivan D., Haynes K., Bille J., Boerlin P., Rodero L., Lloyd S., Coleman D.: Widespread geographic distribution of oral Candida dubliniensis strains in HIV-infected individuals. J. Clin. Microbiol. 35: 960-964 (1997) 4. Sullivan D„ Moran G., Donnelly S., Gee S., Pinjon E., Coleman D.C.: Candida dubliniensis: An update. Rev. Iberoam. Micol. 16: 72-76 (1999) 5. Meier-Kriesche H.U., Ojo A., Hanson J., et al.: Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 669. 885-889 (2000) 6. Alexander B.D., Perfect, J.R.: Antifungal resistance trends towards the year 2000. Implications for therapy and ¡new approaches. Drugs 54: 657-678 (1997) 7. Moran G.P., Sanglard D., Donelly S.M., Shanley D.B., Sullivan D.J., Coleman D.C.:, Identification and expression of multidrug transporters responsible for fluconazole resistance in C. dubliniensis. Antimicrob. Agents Chemother. 42. 1819-1830 (1998) 8. Bicandi J., San Millan R., Moragues M.D., Cebas G., Coleman D.C., Quindos G., Ponton J.: Rapid identification of Candida dubliniensis by indirect immunofluoresence. J. Clin. Microbiol, 3&. 2428-2433 (1998) 9. Kurzai O., Heinz W.J., Sullivan D.J., et al.: Rapid PCR test for discrimination between Candida albicans and Can¬dida dubliniensis isolates using primers derived from the pH-regulated PHR-1 and PHR-2 genes of C. albicans. J. Clin. Microbiol. 37: 1587-1590.(1999) 10. Bille J.: When should Candida isolates be tested for susceptibility to azole antifungal agents? Eur. J. Clin. Microbiol. Infect. Dis. 38: 281-282 (1997) 11. Sanglard D., Odds F.C.: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2. 73-85 (2002) 12. Rex J.H., Bennett J.E., Sugar A.M., et al.: A randomized trial comparing fluconazole with amphotericin B, for the treatment of candidaemia in patients without neutropenia. N. Engl. J. Med. 331: 1325-1330 (1994) 13. Kollia K„ Arabatzis M., Kostoula O., Kostourou A., Velegraki A., Belessiotou E., Lazou A.: Clavispora (Candida) lusitaniae susceptibility profiles and genetic diversity in three tertiary hospitals (1998-2001). int. J. Antimicrob. Agents 22. 458-460 (2003) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2004 – ANNUAL SUBSCRIPTION 2004 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|